BNT327 Optimized Dose

Phase 2Small molecule

BNT327 Optimized Dose is one of 20 small molecule programs targeting Locally Advanced Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Breast CancerActive, not recruiting

Extensive-Stage Small-Cell Lung CancerActive, not recruiting

Locally Advanced Breast CancerPhase 2

Active, not recruiting

Extensive-Stage Small-Cell Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Extensive-Stage Small-Cell Lung Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Phase 3

7 2

Vepesid

AAvyxa

Phase 3

12 3

Paraplatin

AAvyxa

Phase 3

11 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

5 5

Imfinzi

AstraZeneca

Phase 2

5 6

Tarlatamab-Dznl

Amgen

Phase 2

5 7

Avastin

Roche

Phase 2

1 8

BL-B01D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

2 9

Ceralasertib

AstraZeneca

Phase 2

1 10

PD-1 Monoclonal Antibody

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Active, not recruiting

Extensive-Stage Small-Cell Lung Cancer

NCT06449209

Q2 2029

Phase 2Active, not recruiting

Locally Advanced Breast Cancer

NCT06449222

Clinical

Trials by Indication[1]

Extensive-stage Small-cell Lung Cancer1 trial

A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer

Active, not recruiting· BioNTech logo

BioNTech·Phase 2·NCT06449209·110 enrolled

Locally Advanced Breast Cancer1 trial

A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer

Active, not recruiting· BioNTech logo

BioNTech·Phase 2·NCT06449222·83 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BNT327 Optimized Dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BNT327 Optimized Dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BNT327 Optimized Dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioNTech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BioNTech

BNT327 Optimized Dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2029

Trials by Indication[1]

Extensive-stage Small-cell Lung Cancer1 trial

Locally Advanced Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News